Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where U. Alshuth is active.

Publication


Featured researches published by U. Alshuth.


Journal of Hepatology | 2011

447 DIFFERENCES IN DEMOGRAPHICS AND TREATMENT OUTCOME OF CHRONIC HEPATITIS C (CHC) PATIENTS OF DIFFERENT EUROPEAN ORIGIN TREATED WITH PEGINTERFERON ALFA-2A (40KDA) AND RIBAVIRIN (PEG/RBV)

T. Lutz; K. Boeker; G. Moog; Axel Baumgarten; Christoph Eisenbach; W. Schmidt; M. Waizmann; B. Bokemeyer; S. Pape; M. Roessle; Albrecht Stoehr; J. Lohmeyer; T. Witthoeft; B. Möller; H. Loehr; Eckart Schott; U. Alshuth; D. Hueppe

By both methods, depression was usually identified by Week 12, was related to CR2b dose, and was frequent on 640ug CR2b and PEG2b (25–35%). The two lower doses of CR2b had lower rates of depression by both methods. Multivariate analysis showed BDI scores >20 (moderate depression) were associated with lower rates of viral negativity at end of treatment; SVR12 data appear to be equivalent for all four doses (data not shown). Conclusions: Depression was a common problem by Week 12 on PEG2b and on the highest dose of CR2b (640 ug) whether measured by clinic visits or BDI self-report. The lower rates of depression on 320ug and 480ug CR2b evident through Week 48 may offer an important advance in the treatment of HCV. Final 72-week results will be presented at the meeting.


Journal of Hepatology | 2013

875 REAL-WORLD EFFICACY AND SAFETY OF BOCEPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY

G. Moog; A. Schober; C. Antoni; H.R. Bruch; A. Herrmann; C. John; H. Steffens; M. Leuschner; Ulrich Spengler; Bernd Moeller; K. Isernhagen; D. Hueppe; U. Alshuth; Stefan Mauss


Journal of Hepatology | 2013

830 CHOLESTEROL LEVELS AND PRESENCE OF DIABETES PREDICT EARLY VIROLOGICAL RESPONSE TO TRIPLE THERAPY WITH TELAPREVIR, PEG-INTERFERON alfa-2a 180 μg AND RIBAVIRIN IN CHRONIC HEPATITIS C

E. Jaeckel; E Zehnter; C. John; R. Heyne; G. Teuber; W. Schiffelholz; S. Christensen; C. Antoni; S. Pape; M. Roessle; H. Loehr; S. Stoll; U. Alshuth; D. Hueppe; Stefan Mauss; Michael P. Manns


Journal of Hepatology | 2012

1139 VIRAL RESPONSE AT WEEK 2 AS A PREDICITIVE FACTOR FOR RVR IN CHRONIC HCV GENOTYPE 1 INFECTION TREATED WITH PEGINTERFERON ALFA-2A (PEG) AND RIBAVIRIN (RBV)

Stefan Mauss; T. Lutz; K. Boeker; R. Link; G. Moog; Albrecht Stoehr; Axel Baumgarten; C. John; R. Heyne; Christoph Eisenbach; W. Schiffelholz; G. Teuber; B. Weber; Eckart Schott; H. Hillenbrand; U. Alshuth; D. Hueppe; Peter Buggisch


Journal of Hepatology | 2012

1149 PREDICTIVE FACTORS FOR NONRESPONSE IN GENOTYPE 2/3 INFECTED CHRONIC HEPATITIS C (CHC) PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (PEG) AND RIBAVIRIN (RBV) IN REAL LIFE SETTING

Jörg Petersen; T. Lutz; R. Link; G. Moog; Axel Baumgarten; Eckart Schott; W. Schmidt; T. Witthoeft; E. Schnaitmann; M. Seidel; A. Rieke; K.-G. Simon; A. Herrmann; Christoph Herold; Dietmar M. Klass; U. Alshuth; Peter Buggisch; Stefan Mauss; D. Hueppe


Journal of Hepatology | 2011

454 PREDICTIVE FACTORS OF THROMBOCYTOPENIA IN TREATMENT OF CHRONIC HEPATITIS C (CHC) PATIENTS WITH PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN

Stefan Mauss; A. Schober; T. Lutz; G. Moog; Marcus Schuchmann; R. Heyne; C. John; W. Schiffelholz; Axel Baumgarten; K.H. Hey; Christoph Eisenbach; G. Teuber; W. Schmidt; H.R. Bruch; P. Geyer; U. Alshuth; D. Hueppe


Journal of Hepatology | 2011

404 DOSE REDUCTION OF PEGINTERFERON ALFA-2A (PEG) IN COMBINATION WITH RIBAVIRIN (RBV) IN CHRONIC HEPATITIS C (CHC) PATIENTS: IMPACT ON VIROLOGICAL RESPONSE UNDER REAL LIFE CONDITIONS

K. Boeker; Stefan Mauss; D. Hueppe; Marcus Schuchmann; W. Schiffelholz; Axel Baumgarten; Christoph Eisenbach; M. Roessle; Peter Buggisch; J. Lohmeyer; T. Witthoeft; B. Möller; H. Loehr; Eckart Schott; U. Alshuth; E Zehnter


Journal of Hepatology | 2009

651 ROLE OF RVR AND VIRAL LOAD ON SVR IN TREATMENT OF GT3 HEPATITIS C PATIENTS WITH PEGINTERFERON ALFA-2A (PEG) AND RIBAVIRIN (RBV) IN REAL LIFE

E Zehnter; D. Hueppe; Stephan Kaiser; A. Schober; Marcus Schuchmann; K. Boeker; G. Moog; W. Schiffelholz; S. Pape; R. Heyne; F. Ackermann; W. Schmidt; C. John; J. Lohmeyer; K.H. Hey; U. Alshuth; Stefan Mauss


Journal of Hepatology | 2008

842 EFFICACY AND TOLERABILITY OF PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN IN GENOTYPE 4 PATIENTS WITH CHRONIC HEPATITIS C (CHC) UNDER REAL LIFE CONDITIONS

E Zehnter; Stefan Mauss; Stephan Kaiser; K. Boeker; T. Lutz; R. Heyne; C. John; G. Moog; A. Schober; R. Pfaff; A. Zipf; S. Racky; J. Lohmeyer; B. Bokemeyer; B. Kallinowski; T. Witthoeft; U. Alshuth; D. Hueppe


Journal of Hepatology | 2008

812 THE ROLE OF CHOLESTEROL ON SUSTAINED VIROLOGICAL RESPONSE (SVR) IN THE TREATMENT OF GENOTYPE-1 INFECTED HEPATITIS C (CHC) PATIENTS WITH PEGINTERFERON-ALFA-2A (PEG) AND RIBAVIRIN (RBV)

Stefan Mauss; E Zehnter; D. Hueppe; K. Kaiser; K. Boeker; T. Lutz; R. Heyne; C. John; G. Moog; A. Schober; R. Pfaff; A. Zipf; S. Racky; J. Lohmeyer; B. Bokemeyer; B. Kallinowski; T. Witthoeft; U. Alshuth

Collaboration


Dive into the U. Alshuth's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

G. Teuber

Goethe University Frankfurt

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

B. Möller

Free University of Berlin

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge